Genmedica Therapeutics, a Barcelona, Spain-based development stage biotechnology company focused on type 2 diabetes, has raised €3m in funding.
The round was led by Caixa Capital Risc, with participation from Emprèn BCN, Uninvest, VentureCap, private investors including Pont Mestres & Associates and family offices.
The company intends to use the funds to advance clinical trials and complete its product offering.
Founded in 2004 and led by CEO Alec Mian, Ph.D., Stephen Donoghue, Ph.D., VP Clinical Development, Genmedica Therapeutics develops a line of compounds with anti-diabetic activity, as well as therapeutics for dyslipidemia, obesity, inflammatory, and cardiovascular diseases.
FinSMEs
01/10/2011